Clinical Trial

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-20; most recent amendment 2025-05-08.
Trial Details
NCT Number NCT06333249
Lead Sponsor Beacon Therapeutics
Conditions X-Linked Retinitis Pigmentosa
Enrollment 14 participants
Start Date 2021-04-13
Primary Completion 2023-04-11 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-12